NEW YORK--Innovir Laborato ries here announced last month that it has gained additional US patent rights covering the use of oligozymes in pharmaceutical and genomic research, with four patent applications being allowed and two new patents issued. Innovir already holds three issued patents, eight allowed patent applications, and 20 patent pending applications for oligozyme-based technology.
In addition, the company has corresponding foreign patent rights and has exclusively licensed some related patents from Yale University. "These patents further enhance Innovir's ability to harness oligozymes' strong potential for defining which genes cause certain diseases and which are good targets for drug research," commented Thomas Sharpe, the company's president and CEO. Innovir is a majority-owned subsidiary of VIMRX Pharmaceuticals.